BeiGene’s BRUKINSA wins accelerated approval from the FDA for MCL
Category: #health  By Mateen Dalal  Date: 2019-11-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

BeiGene’s BRUKINSA wins accelerated approval from the FDA for MCL
  • BRUKINSA is the first product from BeiGene to get approval from the FDA
     
  • 84% of patients who are talking BRUKINSA have achieved an ORR

BeiGene, Ltd., a biopharmaceutical firm focused on the development and commercialization of innovative immuno-oncology drugs to treat cancer, recently announced the United States Food and Drug Administration (FDA) has given an accelerated approval to BRUKINSA (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) found in adult patients who have received minimum of one therapy before.

BRUKINSA is reportedly the first product discovered by BeiGene that has been approved. This has become an important milestone for the company’s aim to transform treatment for all cancer patients worldwide. The accelerated approval given by the FDA is based on the overall response rate (ORR).

BeiGene’s CEO, Co-Founder and Chairman, John V. Oyler stated that the company has been making efforts to improve the outcomes for people suffering from cancer across the world and the approval will help the company step a little closer to their goal of providing the best quality therapies to patients.

Oyler further added that the approval by FDA for BRUKINSA right after the Breakthrough Therapy designation was given for the indication, further validates it as the prime option for treatment for people who are suffering from refractory or relapsed MCL.

Meghan Gutierrez, CEO of Lymphoma Research Foundation commented that the approval of BRUKINSA as a second-line therapy represents a major advancement in the treatment of mantle cell lymphoma. Varied and expanded options for treatment are capable of transforming the experience and providing a chance for patients living with mantle cell diagnosis.

Jane Huang, M.D., BeiGene’s Chief Medical Officer of Hematology stated that BRUKINSA happens to be a BTK inhibitor which was originally designed to amplify the target occupancy and lessen the off-target binding. The company’s broad development program has enrolled over 1,600 patients globally since the inhibitor entered the clinic in 2014.  

 

Source Credit- https://finance.yahoo.com/news/u-fda-grants-beigene-brukinsa-212048146.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Airtel and Tata Group team-up to compete Jio’s 5G technology
Airtel and Tata Group team-up to compete Jio’s 5G technology
By Mateen Dalal

Bharti Airtel and Tata Group have entered into a strategic partnership to challenge Jio's ‘made-in-India’ 5G technology. The two companies are focusing on deploying 5G radio and core solutions, based on Open-RAN, which Airtel has...

NSW offers $480Mn EV package, waives stamp duty on EVs
NSW offers $480Mn EV package, waives stamp duty on EVs
By Mateen Dalal

In a bid to achieve net-zero emissions by 2050, the Government of New South Wales has committed to invest USD 480 million in a recent budget to encourage the adoption of electric vehicles, including limited USD 3,000 rebates along with removal of sta...

PwC announces ‘New Equation’ strategy to create 100,000 jobs
PwC announces ‘New Equation’ strategy to create 100,000 jobs
By Mateen Dalal

U.K based-PricewaterhouseCoopers or PwC has announced a new global strategy-The New Equation, which will see the company spend nearly USD 12 billion over a span of five years to create nearly 100,000 job roles across 155 of its territory firms in reg...